Shopping Cart
- Remove All
Your shopping cart is currently empty
Mito-LND
🥰Excellent
Catalog No. T9211Cas No. 2361564-49-8
Alias Mito-Loidamine
Mito-LND (Mito-Loidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation.
Mito-LND
🥰Excellent
Purity: 98.34%
Catalog No. T9211Alias Mito-LoidamineCas No. 2361564-49-8
Mito-LND (Mito-Loidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $79 | In Stock | |
| 5 mg | $169 | In Stock | |
| 10 mg | $283 | In Stock | |
| 25 mg | $469 | In Stock | |
| 50 mg | $643 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $262 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Questions
View MoreBatch Information
Select Batch
Purity:98.34%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | Mito-LND (Mito-Loidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation. |
| In vitro | Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 of 0.74 μM and 0.69?μM, respectively. Mito-LND inhibits mitochondrial complex I and II activities with IC50 of 1.2 μM and 2.4?μM, respectively in H2030BrM3 cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells. Mito-LND decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling. |
| In vivo | Mito-LNDtreatment markedly enhanced potency against both lung cancer progression and metastasis. Mito-LND also decreases the rate of growth of A549 tumor xenografts. Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells. |
| Synonyms | Mito-Loidamine |
| Molecular Weight | 801.62 |
| Formula | C43H45BrCl2N3OP |
| Cas No. | 2361564-49-8 |
| Smiles | O=C(NCCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C4=NN(CC5=CC=C(Cl)C=C5Cl)C6=C4C=CC=C6.[Br-] |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (56.14 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.49 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Mito-LND | purchase Mito-LND | Mito-LND cost | order Mito-LND | Mito-LND chemical structure | Mito-LND in vivo | Mito-LND in vitro | Mito-LND formula | Mito-LND molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.